Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$20.13 -1.3%	$23.43	$12.21 ▼ $40.70	$563.58M	-0.2	750,603 shs	503,622 shs
SAGE Sage Therapeutics	$8.68	$8.92	$4.62 ▼ $11.44	$543.54M	0.26	3.63 million shs	N/A
SVRA Savara	$3.27 -0.6%	$2.54	$1.89 ▼ $4.70	$565.19M	0.4	1.25 million shs	843,236 shs
ZNTL Zentalis Pharmaceuticals	$1.76 -3.3%	$1.43	$1.01 ▼ $5.44	$126.97M	1.71	1.22 million shs	455,861 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+2.20%	+1.24%	-23.28%	-9.57%	-44.63%
SAGE Sage Therapeutics	0.00%	0.00%	-1.14%	+33.13%	+7.03%
SVRA Savara	-0.60%	+6.47%	+23.68%	+46.88%	-23.84%
ZNTL Zentalis Pharmaceuticals	-1.62%	+10.98%	+26.39%	+45.60%	-40.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	1.9252 of 5 stars	3.4	0.0	0.0	2.3	2.5	0.6
SAGE Sage Therapeutics	3.6895 of 5 stars	2.0	5.0	4.1	2.1	1.7	0.6
SVRA Savara	2.4551 of 5 stars	3.4	0.0	0.0	3.1	3.3	0.6
ZNTL Zentalis Pharmaceuticals	1.9892 of 5 stars	3.3	2.0	0.0	3.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$46.13	129.14% Upside
SAGE Sage Therapeutics	1.93	Reduce	$7.85	-9.56% Downside
SVRA Savara	2.83	Moderate Buy	$6.17	88.58% Upside
ZNTL Zentalis Pharmaceuticals	2.67	Moderate Buy	$8.20	365.91% Upside

Current Analyst Ratings Breakdown

Latest ZNTL, ANAB, SVRA, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	SVRA Savara	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$5.00 ➝ $6.00
8/15/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$2.00 ➝ $5.00
8/12/2025	ANAB AnaptysBio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $20.00
8/7/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $45.00
8/7/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2025	ZNTL Zentalis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00
7/24/2025	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $80.00
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$123.16M	4.58	N/A	N/A	($1.60) per share	-12.58
SAGE Sage Therapeutics	$41.24M	13.18	N/A	N/A	$5.89 per share	1.47
SVRA Savara	N/A	N/A	N/A	N/A	$0.70 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	1.88	N/A	N/A	$3.81 per share	0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.48	N/A	N/A	N/A	-107.66%	-366.98%	-30.58%	11/4/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$4.89	N/A	N/A	N/A	-427.78%	-67.10%	-58.42%	11/4/2025 (Estimated)
SVRA Savara	-$95.88M	-$0.50	N/A	N/A	N/A	N/A	-69.05%	-54.84%	11/11/2025 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$2.26	N/A	N/A	N/A	N/A	-51.62%	-40.28%	11/11/2025 (Estimated)

Latest ZNTL, ANAB, SVRA, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A
8/6/2025	Q2 2025	ANAB AnaptysBio	-$1.50	-$1.34	+$0.16	-$1.34	$11.55 million	$22.26 million
8/6/2025	Q2 2025	ZNTL Zentalis Pharmaceuticals	-$0.56	-$0.37	+$0.19	-$0.37	N/A	N/A
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	-$0.79	+$0.17	-$0.79	$16.69 million	$31.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.22	8.22
SAGE Sage Therapeutics	N/A	9.16	9.13
SVRA Savara	0.25	11.08	11.08
ZNTL Zentalis Pharmaceuticals	N/A	7.99	7.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
SAGE Sage Therapeutics	99.22%
SVRA Savara	87.93%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
SAGE Sage Therapeutics	5.50%
SVRA Savara	5.33%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	28.00 million	18.62 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
SVRA Savara	20	172.84 million	163.63 million	Optionable
ZNTL Zentalis Pharmaceuticals	160	72.14 million	70.76 million	Optionable

ZNTL, ANAB, SVRA, and SAGE Headlines

Recent News About These Companies

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

2 hours ago | globenewswire.com

Zentalis Pharmaceuticals Announces New Chief Legal Officer

August 26 at 9:45 PM | msn.com

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

August 26 at 4:05 PM | globenewswire.com

Guggenheim Remains a Buy on Zentalis Pharmaceuticals (ZNTL)

August 19, 2025 | theglobeandmail.com

Zentalis Pharmaceuticals (ZNTL) Gets a Buy from TD Cowen

August 18, 2025 | theglobeandmail.com

Zentalis (ZNTL) Q2 Loss Narrows 70%

August 18, 2025 | theglobeandmail.com

Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

HC Wainwright Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to "Strong-Buy"

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold

August 10, 2025 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

August 9, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Primecap Management Co. CA

August 9, 2025 | marketbeat.com

Zentalis price target lowered to $5 from $6 at Wells Fargo

August 8, 2025 | msn.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $5.00 by Analysts at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.

August 7, 2025 | marketbeat.com

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

August 6, 2025 | globenewswire.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by Brokerages

August 6, 2025 | marketbeat.com

GSA Capital Partners LLP Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

August 3, 2025 | marketbeat.com

Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

Decheng Capital LLC Lowers Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

July 30, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company

July 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, ANAB, SVRA, and SAGE Company Descriptions

AnaptysBio NASDAQ:ANAB

$20.13 -0.27 (-1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$20.12 -0.01 (-0.05%)

As of 04:31 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Sage Therapeutics NASDAQ:SAGE

$8.68 0.00 (0.00%)

As of 07/31/2025

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Savara NASDAQ:SVRA

$3.27 -0.02 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 -0.05 (-1.53%)

As of 05:34 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.76 -0.06 (-3.30%)

Closing price 04:00 PM Eastern

Extended Trading

$1.83 +0.07 (+3.98%)

As of 05:26 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time